Semaglutide and tirzepatide are medications primarily used for type 2 diabetes and chronic weight management. They are GLP-1

receptor agonists, mimicking the natural hormone GLP-1 to regulate blood sugar and appetite.

They increase insulin secretion, slow gastric emptying (making you feel full longer), and act on brain receptors to decrease appetite.

Tirzepatide is a dual GLP-1 and GIP receptor agonist, targeting an additional hormone pathway, often offering stronger insulin

sensitivity and weight reduction effects.

Once weekly subcutaneous injection via pen device (upper arms, abdomen, or thighs).

Common side effects include nausea, vomiting, diarrhea or constipation, abdominal pain, and decreased appetite. Most side effects are

mild and decrease over time.

Serious side effects may include pancreatitis, gallbladder problems, hypoglycemia (especially with other diabetes medications), and

thyroid tumors (risk in humans unknown; seen in animals).

They are often long-term treatments. Stopping may lead to weight regain, so continued use under medical supervision is typically

recommended for sustained results.

No. Combining semaglutide and tirzepatide increases side effect risks and is not recommended.

Effectiveness varies by individual. Tirzepatide may offer slightly more weight loss due to its dual-action mechanism, but both are highly

effective when used as part of a comprehensive weight management program.

If less than 4-5 days late, take it as soon as remembered. If longer, skip and resume the regular schedule. Never double up on doses.

Yes. Both medications are FDA-approved for weight control alongside lifestyle changes and have been shown to produce significant

weight loss in clinical trials.

Consult your healthcare provider before drinking alcohol while taking these medications, as alcohol may affect blood sugar levels and

medication effectiveness.